Kronos Bio lands $105 mln Series A

San Mateo, California-based Kronos Bio, which is focused on researching and developing first-in-class therapies “that modulate historically undruggable targets,” has secured $105 million in Series A funding. The investors included Vida Ventures LLC.

Source: Press Release